|
|
 |
| |
Actelion is on track...
|
THE ACTELION ANNUAL REPORT 2002 |
|
|
|
| |
|
|
|
|
|
|
|
Actelion is on track for growth and profitability ...
|
| |
Tracleer®, a breakthrough in treating pulmonary arterial hypertension (PAH) and our first product on the market, is off to a dynamic start. Revenues are rising, with over CHF 120 million in sales in its first year on the market. Our global sales and marketing organization is growing to capture the full potential in PAH – estimated at USD 400 million to 500 million at peak. Our scientists are exploring new indications for Tracleer® and developing new molecules that are advancing into human trials at a record-breaking pace.
We are preparing to launch Zavesca®, an innovative therapy that we have licensed in to treat type 1 Gaucher’s disease. Actelion is clearly a company on the move ...
|
|
|
|
